Antiviral Drugs - India

India

The Antiviral Drugs market in India is expected to witness significant revenue growth in the coming years.
According to projections, the revenue is estimated to reach ₹€0.39bn in 2024.
Furthermore, the market is anticipated to experience a steady annual growth rate (CAGR 2024-2029) of 2.44%, leading to a market volume of ₹€0.44bn by 2029.
It is worth noting that in a global comparison, United States is expected to generate the highest revenue in the Antiviral Drugs market, with an estimated value of €28,420.00m in 2024.
India is emerging as a key player in the antiviral drugs market, leveraging its strong pharmaceutical industry and affordable drug manufacturing capabilities.

Key regions: Brazil, India, Australia, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Antiviral Drugs market in India has been experiencing significant growth in recent years, with a rising demand for these drugs due to the increasing prevalence of viral diseases in the country.

Customer preferences: Customers in India are becoming increasingly aware of the importance of antiviral drugs in treating viral diseases, which has led to a growing demand for these drugs. In particular, there is a high demand for antiviral drugs that are effective against diseases such as HIV, hepatitis B and C, influenza, and dengue fever.

Trends in the market: One of the key trends in the Antiviral Drugs market in India is the increasing adoption of generic drugs. Generic drugs are cheaper and more affordable than branded drugs, making them more accessible to a wider range of customers. This has led to a significant increase in the production and sale of generic antiviral drugs in the country.Another trend in the market is the growing use of combination therapy. Combination therapy involves the use of two or more antiviral drugs to treat a viral infection. This approach is becoming increasingly popular in India, as it has been shown to be more effective in treating certain viral diseases.

Local special circumstances: India has a large population that is highly susceptible to viral diseases due to factors such as poor sanitation, overcrowding, and a lack of access to healthcare. This has led to a high demand for antiviral drugs in the country, as these drugs are often the only effective treatment for many viral diseases.

Underlying macroeconomic factors: The Antiviral Drugs market in India is also being driven by a number of underlying macroeconomic factors. These include the increasing prevalence of viral diseases in the country, rising healthcare expenditure, and the growing focus on research and development in the pharmaceutical industry. Additionally, the Indian government has implemented a number of policies and initiatives aimed at promoting the production and sale of generic drugs, which has helped to boost the Antiviral Drugs market in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.